...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: What am I missing

CALGARY, Alberta, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), today announces the approval of its COVID-19 clinical trial of apabetalone by the Health Research Ethics Board (HREB) – Biomedical Panel at the University of Alberta. This approval allows for recruitment in the trial to commence. [My emphasis]

“The ethics board approval is an important step towards bringing apabetalone to market to help fight the ongoing COVID-19 pandemic,” said Donald McCaffrey, Resverlogix’s President & CEO.

Seven weeks ago, our leader made the above announcement.  My guess, since the announcement, just in Calgary, over 1,000 have been admitted to critical care.   Many have died!

Hope Eversana will not become disillusioned.  What am I missing?  IS BP behind the stall?

Something is wrong here.  Appears RVX has hit the proverbial brick wall. Yes, many years ago!

With stock dilution we receive disappointment. sidebar and still holding long.

Share
New Message
Please login to post a reply